Ozagrel (CAS: 82571-53-7), also known as OKY-046, is a medication used primarily in Japan for the treatment of various cardiovascular and cerebrovascular disorders. It is a thromboxane A2 (TXA2) synthesis inhibitor that targets platelet activation and aggregation. Ozagrel is typically administered orally or intravenously.
Chemical name: 5-[(4Z)-1,4-dihydro-4-[(5-isopropoxypyridin-3-yl)methylidene]-2,3-dimethyl-2-oxo-1H-imidazol-5-yl]-2-methoxybenzenesulfonic acid Molecular formula: C23H26N2O5S Formula weight: 446.53 g/mol CAS No: 82571-53-7
Top 10 Keywords from Google and Synonyms:
Synonyms: 5-(4-(5-isopropoxy-3-pyridylmethylene)-2,3-dimethyl-1,4-imidazolidinedione)-2-methoxybenzenesulfonic acid, OKY-046, Ozagrel sodium.
Health Benefits of Ozagrel: Ozagrel is primarily used for the treatment of various cardiovascular and cerebrovascular disorders. It is an antiplatelet medication that works by inhibiting the production of thromboxane A2, which is a potent vasoconstrictor and platelet activator. Ozagrel has been used to treat conditions such as myocardial infarction, stroke, atherosclerosis, and thrombosis.
Product Mechanism: Ozagrel works by inhibiting the activity of thromboxane A2 synthase, which is responsible for the synthesis of thromboxane A2. Thromboxane A2 is a potent platelet aggregator and vasoconstrictor that can contribute to the formation of blood clots. By inhibiting the production of thromboxane A2, ozagrel reduces platelet activation and aggregation, which can help prevent the formation of blood clots in the cardiovascular and cerebrovascular systems.
Potential Effects: The primary effect of ozagrel is the inhibition of platelet aggregation, which can help to prevent the formation of blood clots in the cardiovascular and cerebrovascular systems. Ozagrel has also been shown to have anti-inflammatory and antioxidant effects, which may contribute to its efficacy in the treatment of various disorders. In clinical studies, ozagrel has been shown to reduce the risk of recurrent stroke and to improve the outcomes of patients with myocardial infarction.
Safety: Common side effects of ozagrel include gastrointestinal symptoms such as nausea, vomiting, and diarrhea. More serious side effects include bleeding and thrombocytopenia. Ozagrel can also interact with other medications, particularly anticoagulants, and patients should be carefully monitored for potential drug interactions.
Side Effects and Dosing Information: The dosing of ozagrel depends on the indication being treated, the patient's individual characteristics, and the route of administration. Ozagrel is typically administered orally or intravenously. Patients with a history of bleeding or who are taking anticoagulants should not take ozagrel. Patients should also avoid taking nonsteroidal anti-inflammatory drugs (NSAIDs) while taking ozagrel.
Conclusion: Ozagrel is a thromboxane A2 synthesis inhibitor used primarily for the treatment of cardiovascular and cerebrovascular disorders. Its primary mechanism of action is the inhibition of platelet activation and aggregation, which can help to prevent the formation of blood clots. While ozagrel has been shown to be effective in reducing the risk of recurrent stroke and improving the outcomes of patients with myocardial infarction, it can also cause side effects such as bleeding and gastrointestinal symptoms. Patients taking ozagrel should be carefully monitored by a healthcare professional to ensure that its use is safe and effective.
